





25. The compound of claim 1, wherein  is  or  ;

B is  or  ;


$-(CH_2)_n-R_1$ is H, CH_3 , or CH_2CH_3 ;

R_2 , R_3 , R_4 , R_5 , R_8 , R_9 , and R_{10} , independently, are selected from the group consisting of H, F, Cl, and CH_3 ;

R_7 is F; and

R_6 is  .

26. A compound selected from the group consisting of



27. The use of a compound according to any one of claims 1-26 in the manufacture of a medicament for the treatment of a hyperproliferative disease for which a MDM2 inhibitor is indicated.

28. The use of claim 27 wherein the hyperproliferative disease is a cancer.

29. The use of claim 27, wherein the medicament is to be administered with a) a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease or condition, wherein the disease is a cancer and the second therapeutic agent is one or

more of a chemotherapeutic agent, or b) the application of a radiation therapy useful in the treatment of the disease or condition, wherein the disease is a cancer.

30. A kit for human pharmaceutical use comprising (a) a container, (b1) a packaged composition comprising a compound as claimed in any one of claims 1 to 26, and, optionally, (b2) a packaged composition comprising a second therapeutic agent useful in the treatment of a disease or condition of interest, and (c) a package insert containing directions for use of the composition or compositions.